Skip to main content
SpringerLink
Log in

Stereotactic Body Radiotherapy/Stereotactic Ablative Body Radiotherapy for Lung Cancer

  • Chapter
  • First Online:
Computational Surgery and Dual Training

  • 837 Accesses

Abstract

Technological advances in radiation oncology have led to clinical implementation of novel treatment modality. Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) is an emerging treatment paradigm as a result of image-guidance technology and more sophisticated computational treatment planning system. SBRT/SABR, an example of computational radiosurgery, is a continuum of advances in computational surgery. The role of SBRT/SABR is most important in the management of lung cancer for early primary lung cancer and in oligometastatic lung disease. SBRT/SABR combines the challenges of patient/tumor/normal tissues motion with that of meeting the stringent dosimetric requirements of stereotactic radiosurgery (SRS). Target delineation, image guidance, patient immobilization, computer-assisted treatment planning, and delivery are essential in the safe and successful practice of SBRT/SABR. Radio-biologic rationale, technical and clinical aspects of SBRT/SABR in the treatment of both primary and metastatic lung cancer as well as the future challenges will be addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lax I, Blomgren H, Naslund I et al (1994) Stereotactic radiotherapy of malignancies in the abdomen. Acta Oncol 33:677–683

    Article  Google Scholar 

  2. Sandler HM, Curren WJ, Turrisi AT et al (1990) The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 19(1):9–13

    Article  Google Scholar 

  3. Noordijk EM, Poest CE, Hermans J et al (1988) Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 13(2):83–89

    Article  Google Scholar 

  4. Sibley GS, Jamieson TA, Marks LB et al (1998) Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 40: 149–154

    Article  Google Scholar 

  5. Fakiris AJ, McGarry RC, Yiannoutsos CT et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75:677–682

    Article  Google Scholar 

  6. Onishi H, Shirato H, Nagata Y et al (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2:S94–S100

    Article  Google Scholar 

  7. Siva S, MacManus M, Ball D (2010) Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 5(7):1091–1099

    Google Scholar 

  8. Wang S, Liao Z, Wei X et al (2006) Analysis of clinical and dosimetric factors associated with treatment-related pneumontis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66:1399–1407

    Article  Google Scholar 

  9. Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833–4839

    Article  Google Scholar 

  10. Timmerman RD, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early-stage lung cancer. JAMA 303:1070–1076

    Article  Google Scholar 

  11. Senan S, Haasbeek CJ, Antonisse ME et al (2009) Outcomes of stereotactic body radiotherapy (SBRT) in 175 patients with stage I NSCLC aged 75 years and older. J Clin Oncol 27:15s (suppl; abstr 9545)

    Article  Google Scholar 

  12. Haasbeek CJ, Lagerwaard FJ, Antonisse ME et al (2010) Stage I non-small cell lung cancer in patients aged > or = 75 years: outcomes after stereotactic radiotherapy. Cancer 116(2): 406–414

    Article  Google Scholar 

  13. Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27:3290–3296

    Article  Google Scholar 

  14. Onishi H, Araki Y, Shirato H et al (2009) Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 101:1623–1631

    Article  Google Scholar 

  15. Chansky K, Sculier JP, Crowley JJ et al (2009) The IASLC lung cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4(7):792–801

    Article  Google Scholar 

  16. Kiser AC, Detterbeck FC (2001) General aspects of surgical treatment. In: Detterbeck FC, Rivera MP, Socinski M, Rosenmann JE (eds) Diagnosis and treatment of lung cancer. WB Saunders, Philadelphia

    Google Scholar 

  17. Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28(6):928–935

    Article  Google Scholar 

  18. Hurkmans CW, Cuijpers JP, Lagerwaard FJ et al (2009) Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the quality assurance working party of the randomized phase III ROSEL study. Radiat Oncol 4:1

    Article  Google Scholar 

  19. Nagata Y, Matsuo Y, Takayama K et al (2007) Current status of stereotactic body radiotherapy for lung cancer. Int J Clin Oncol 12:3–7

    Article  Google Scholar 

  20. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10

    Google Scholar 

  21. Norihisa Y, Nagata Y, Takayama K et al (2008) Stereotactic body radiotherapy for olignometastatic lung tumors. Int J Radiat Oncol Biol Phys 72(2):398–403

    Article  Google Scholar 

  22. Rusthoven KE, Kavanagh BD, Burri SH et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases and tolerability of high-dose stereotactic body radiation therapy (SBRT) for the treatment of patients with one to three lung metastases. J Clin Oncol 27(10):1579–1584

    Article  Google Scholar 

  23. Zhang H, Xiao J, Li Y et al (2009) Hypofractionated stereotactic body radiation therapy for metastatic lung tumors. Int J Radiat Oncol Biol Phys 75(3):S117

    Article  Google Scholar 

  24. Ren H, Teh B (2010) Clinical outcomes of patients with malignant lung lesions treated with SBRT in five fractions. Int J Radiat Oncol Biol Phys 78(3):S524

    Article  Google Scholar 

  25. Timmerman R, Galvin J, Michalski J et al (2006) Accreditation and quality assurance for radiation therapy oncology group: multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol 45:779–786

    Article  Google Scholar 

  26. Timmerman R, Papiez L, McGarry R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:946–1955

    Article  Google Scholar 

  27. Hara R, Itami J, Komiyama T et al (2004) Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 125:340–344

    Article  Google Scholar 

  28. Yamashita H, Nakagawa K, Nakamura N et al (2007) Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2:21

    Article  Google Scholar 

  29. Uematsu M, Tukui T, Tahara K, Sato N, Shiota A, Wong J (2008) Long-term results of computed tomography guided hypofractionated stereotactic radiotherapy for stage I non-small cell lung cancers. Int J Radiat Oncol Biol Phys 72:S37

    Article  Google Scholar 

  30. Chang JY, Balter PA, Dong L et al (2008) Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72:967–971

    Article  Google Scholar 

  31. Hoyer M, Roed H, Hansen AT et al (2006) Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 66:S128–S135

    Article  Google Scholar 

  32. Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S (2008) Outcomes of risk adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685–692

    Article  Google Scholar 

  33. Zimmermann FB, Geinitz H, Schill S et al (2006) Stereotactic hypofractionated radiotherapy in stage I (T1-2N0M0) non-small-cell lung cancer (NSCLC). Acta Oncol 45:796–801

    Article  Google Scholar 

  34. Guckenberger M, Wulf J, Mueller G et al (2009) Dose–response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74:47–54

    Article  Google Scholar 

  35. Rietzel E, Chen GT, Choi NC et al (2005) Four-dimensional image-based treatment planning: target volume segmentation and dose calculation in the presence of respiratory motion. Int J Radiat Oncol Biol Phys 61:1535–1550

    Article  Google Scholar 

  36. Rietzel E, Liu AK, Doppke KP et al (2006) Design of 4D treatment planning target volumes. Int J Radiat Oncol Biol Phys 66(1):287–295

    Article  Google Scholar 

  37. Underberg RW, Lagerwaard FJ, Cuijpers JP et al (2004) Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys 60(4):1283–1290

    Article  Google Scholar 

  38. Wang L, Hayes S, Paskalev K et al (2009) Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage. Radiother Oncol 91:314–324

    Article  Google Scholar 

  39. van der Geld YG, Lagerwaard FJ, van Sörnsen de Koste JR et al (2006) Reproducibility of target volumes generated using uncoached 4-dimensional CT scans for peripheral lung cancer. Radiat Oncol 1:43

    Article  Google Scholar 

  40. Guckenberger M, Wilbert J, Meyer J et al (2007) Is a single respiratory correlated 4D-CT study sufficient for evaluation of breathing motion? Int J Radiat Oncol Biol Phys 67(5):1352–1359

    Article  Google Scholar 

  41. Hurkmans CW, Lieshout MV, Schuring D et al (2011) Quality assurance of 4D-CT scan techniques in multicenter phase III trial of surgery versus stereotactic radiotherapy (radiosurgery or surgery for operable early stage (stage 1A) non-small-cell lung cancer [ROSEL] study). Int J Radiat Oncol Biol Phys 80(3):918–927

    Article  Google Scholar 

  42. Frank A, Lefkowitz D, Jaeger S et al (1995) Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32:1495–1512

    Article  Google Scholar 

  43. Bury T, Corhay JL, Duysinx B et al (1999) Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer. Eur Respir J 14:1376–1380

    Article  Google Scholar 

  44. Inoue T, Kim EE, Komaki R et al (1995) Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36:788–793

    Google Scholar 

  45. van Loon J, Grutters J, Wanders R et al (2008) Follow-up with (18) FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer 45:588–595

    Article  Google Scholar 

  46. Silvestri GA, Gould MK, Margolis ML et al (2007) Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132: 178S–201S

    Article  Google Scholar 

  47. Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496–507

    Article  Google Scholar 

  48. Berghmans T, Dusart M, Paesmans M et al (2008) Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3:6–12

    Article  Google Scholar 

  49. Rosenzweig K, Greco C (2008) Non-small cell lung cancer. In: Paulino AC, Teh BS (eds) PET-CT in radiotherapy treatment planning. Saunders Elsevier, Philadelphia

    Google Scholar 

  50. Henderson MA, Hoopes DJ, Fletcher JW et al (2010) A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(3):789–795

    Article  Google Scholar 

  51. Coon D, Gokhale AS, Burton SA et al (2008) Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin Lung Cancer 9(4):217–221

    Article  Google Scholar 

  52. Hoopes DJ, Tann M, Fletcher JW et al (2007) FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 56:229–234

    Article  Google Scholar 

  53. Burdick MJ, Stephans KL, Reddy CA et al (2010) Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 78(4): 1033–1039

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Houston Methodist Hospital, Cancer Center and Research Institute, Houston, TX, USA

    Hua Ren & Bin S. Teh

  2. Department of Radiation Oncology, Cancer Hospital (Institute), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People’s Republic of China

    Hua Ren

  3. Department of Surgery, Houston Methodist Hospital, Houston, TX, USA

    Shanda Blackmon

Authors
  1. Hua Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shanda Blackmon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin S. Teh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bin S. Teh .

Editor information

Editors and Affiliations

  1. Dept of Computer Science, University of Houston, Houston, Texas, USA

    Marc Garbey

  2. Dept. Surgery, The Methodist Hospital Research Institut, Houston, Texas, USA

    Barbara Lee Bass

  3. Department of Surgery, University of Florida, Gainesville, Florida, USA

    Scott Berceli

  4. Labo. Sciences de l'Images, de l'Informatique et de la Télédétection, Université Strasbourg I ENSPS, Illkirch, France

    Christophe Collet

  5. Biomedical Engineering Department, Politecnico di Milano, Milano, Italy

    Pietro Cerveri

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer New York

About this chapter

Cite this chapter

Ren, H., Blackmon, S., Teh, B.S. (2014). Stereotactic Body Radiotherapy/Stereotactic Ablative Body Radiotherapy for Lung Cancer. In: Garbey, M., Bass, B., Berceli, S., Collet, C., Cerveri, P. (eds) Computational Surgery and Dual Training. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8648-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8648-0_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8647-3

  • Online ISBN: 978-1-4614-8648-0

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation